Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cIAI

Abdominal Abscess Clinical Trial

Official title:

A Multicenter, Open Label Study to Evaluate the Efficacy and Safety of Tigecycline to Treat Complicated Intra-Abdominal Infections (cIAI) in Hospitalized Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00488306
• Other study ID #: 3074A1-101994
• Status: Completed
• Phase: Phase 4
• First received: June 18, 2007
• Last updated: July 6, 2009
• Start date: August 2006
• Est. completion date: August 2007

Study information

• Verified date: July 2009
• Source: Wyeth is now a wholly owned subsidiary of Pfizer
• Contact: n/a
• Is FDA regulated: No
• Health authority: Taiwan: Department of Health
• Study type: Interventional

Clinical Trial Summary

In light of tigecycline's activity against these resistant bacteria, tigecycline may represent a viable new therapy for complicated intra-abdominal infections.

Description:

To evaluate the efficacy and safety of tigecycline to treat complicated intra-abdominal infections in hospitalized patients. Both the clinical response profile and the microbiological response profile will be assessed. The primary endpoint will be clinical response within the microbiological evaluable population at the test-of-cure assessment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: August 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Hospitalized male or female patients greater than or equal to 18 years of age.

• Patients must be a candidate for or have had a laparotomy, or laparoscopy of an intra-abdominal abscess.

• Patients with a complicated intra-abdominal infection such as:

• an intra-abdominal abscess;

• an intra-abdominal abscess (including liver and spleen) that develops in a post-operative patient after receiving > 48 hours and less than or equal to 5 days of a non-study antibiotic. An intra-abdominal culture must be obtained from the infected site.

• appendicitis complicated by perforation (grossly visible) and abscess and/or periappendiceal abscess;

• perforated diverticulitis complicated by abscess formation or fecal contamination;

• complicated cholecystitis with evidence of perforation or empyema;

• perforation of the large or small intestine with abscess, or fecal contamination;

• purulent peritonitis or peritonitis associated with fecal contamination;

• gastric or duodenal ulcer perforation with symptoms lasting at least 24 hours prior to operation;

• traumatic bowel perforation with symptoms lasting at least 12 hours prior to operation.

Exclusion Criteria:

• Patients with any concomitant condition that, in the opinion of the investigator, would preclude an evaluation of a response or make it unlikely that the contemplated course of therapy or follow-up visits could be completed.

• Active or treated leukemia or systemic malignancy that required treatment with chemotherapy, immunotherapy, radiation therapy or antineoplastic therapy within the past 3 months, or any metastatic malignancy to the abdomen with life expectancy less than 6 months.

• Anticipated length of antibiotic therapy less than 5 days.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Abdominal Abscess
• Intraabdominal Infections

Intervention

Drug:
• tigecycline

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Wyeth is now a wholly owned subsidiary of Pfizer

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary efficacy endpoint will be clinical response within the clinically evaluable population at the test-of-cure assessment.
Secondary	microbiological response (eradicated, persistence, superinfection, or indeterminate) at the patient level, microbiological response (eradicated, persistence, or indeterminate) at the pathogen level (overall and resistant pathogens) clinical